Semaglutide vs Tirzepatide Side Effects: STEP 1 vs SURMOUNT-1

You are comparing two medications, and the question on your mind is simple: which one has side effects I can actually live with?

This is a legitimate concern, and it deserves a straightforward answer. Nausea, diarrhea, and other GI side effects are real. They happen with both medications. The research shows subtle differences between semaglutide and tirzepatide in early trials, but the most recent head-to-head data paints a more nuanced picture. Here is what the clinical evidence actually shows, and what it means for your decision.

The GLP-1 Side Effect Profile: Shared Mechanism, Same Baseline

Both semaglutide and tirzepatide are GLP-1 receptor agonists. Semaglutide activates GLP-1 only. Tirzepatide activates both GLP-1 and GIP receptors. Despite the difference in target, both medications produce nearly identical gastrointestinal side effects because the GLP-1 mechanism is the primary driver of these effects.

The shared mechanism explains why both medications slow gastric emptying (the rate at which food leaves your stomach), which is the root cause of nausea, vomiting, and some types of constipation and diarrhea. Both medications also directly stimulate the brain’s nausea centers through chemoreceptor activation. These are biological facts, not product differences.

Which side effects should you expect? The most common ones are:

• Nausea
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain
• Dyspepsia (indigestion)

These are dose-dependent and typically worst during dose escalation periods. They improve as your body adjusts, but the timeline varies by individual.

STEP 1 vs SURMOUNT-1: Cross-Trial Comparison

Here is where the data gets interesting. The STEP 1 trial studied semaglutide, and the SURMOUNT-1 trial studied tirzepatide. They were not head-to-head studies, so direct comparisons have limits. Different patient populations, different trial designs, and different protocols create noise. But the trend is consistent enough to be meaningful.

These percentages reflect the proportion of trial participants who reported the side effect at any point during the study.^[1][2] Important context: most of these side effects appeared during dose escalation and improved or resolved by the end of the trial as patients’ bodies adapted.

What does this cross-trial comparison suggest? Tirzepatide showed a slightly lower incidence of nausea and significantly lower vomiting rates. The diarrhea and constipation rates were also lower, though the differences are smaller.

But here is the critical caveat: these were not identical patient populations, and the trial protocols differed. The STEP 1 population had a different baseline weight, BMI, and age distribution than SURMOUNT-1. You cannot simply conclude that tirzepatide is better tolerated without controlling for these variables.

SURMOUNT-5: The Head-to-Head Reality Check

In 2025, SURMOUNT-5 was published, a direct head-to-head trial comparing semaglutide to tirzepatide in the same patient population, with the same protocol.^[3] This is the gold standard for comparison.

The result? Broadly similar tolerability.

Both medications caused nausea, diarrhea, and other GI side effects at comparable rates in the head-to-head setting.^[3] Neither drug emerged as clearly “better tolerated” than the other when studied under identical conditions.

This finding is important and often overlooked. The differences seen in STEP 1 vs SURMOUNT-1 appear to reflect differences in how the studies were conducted and who enrolled, not fundamental differences in medication tolerability.

What Accounts for Individual Variation?

If the medications are so similar in terms of side effects, why do some patients tolerate one much better than the other?

Several factors matter:

Genetic and metabolic factors. Some people’s gastric systems are more sensitive to slowed emptying. Genetic variations in receptors, gastric motility, and nausea pathways likely play a role. This is not predictable in advance – you cannot test for it beforehand.

Dose escalation speed. Both medications are started at a low dose and increased gradually over weeks or months. Patients who dose-escalate more slowly tend to experience fewer side effects. Some providers use micro-dosing protocols, which start at even lower doses. This matters more than which specific medication you are taking.

Food and hydration choices. What and how much you eat matters tremendously. Patients who eat smaller, lighter meals and stay well-hydrated report fewer symptoms. The medication does not change this; rather, the medication makes it more obvious.

Concurrent medical conditions. Patients with a history of gastroparesis (delayed stomach emptying) or GERD may struggle more with either medication. Patients taking other medications that affect GI motility may have additional challenges.

Expectation and nocebo effects. If you expect nausea, you may perceive it more acutely or attribute benign sensations to the medication. This is not “all in your head” – nocebo effects are real physiological phenomena – but they are one reason some patients experience more symptoms than others even on identical medication.

Serious and Rare Side Effects: Similar Risk Across Both

Both medications carry similar risks for serious but rare side effects:

Gallbladder disease. Both semaglutide and tirzepatide are associated with a roughly 2-fold increased risk of gallbladder disease, including gallstones and cholecystitis.^[1][2] This risk is real but affects a small percentage of patients. Your provider should screen for gallbladder disease risk factors before starting either medication.

Pancreatitis. Both medications slightly elevate the risk of acute pancreatitis compared to placebo, though the absolute risk remains low. Patients with a personal or family history of pancreatitis require careful evaluation.

Thyroid C-cell tumors. Both medications carry a black box warning for thyroid C-cell adenomas and carcinomas based on animal studies. The human clinical relevance is unclear, but the warning exists for both medications.

Gastroparesis. Both medications slow gastric emptying, which is the mechanism that reduces appetite. In rare cases, this can progress to symptomatic gastroparesis (severe, persistent stomach paralysis). This is more common in patients with underlying risk factors.

The serious adverse event profiles are essentially identical because the mechanism is the same. Neither medication emerges as clearly safer in terms of rare but serious events.

Injection Site Reactions: Both Medications

Both semaglutide and tirzepatide are administered as subcutaneous injections once weekly. Injection site reactions are possible with both medications but are generally mild and brief.

Common injection site reactions include:

• Redness
• Swelling
• Bruising
• Itching or mild pain

These typically appear within hours of injection and resolve within a day or two. They are not usually severe enough to warrant stopping the medication. Over time, alternating injection sites and proper injection technique reduce the frequency and severity of these reactions.

Some patients develop nodules or lipohypertrophy (thickened fatty tissue) at injection sites with frequent injections. This is manageable with good site rotation.

The Practical Reality: You Cannot Predict Individual Response

Here is what clinical evidence does not tell you: how you personally will respond to each medication.

Some patients tolerate semaglutide beautifully and cannot take tirzepatide due to severe nausea. Others experience the opposite. Your individual neurobiology, GI anatomy, and baseline metabolism all matter. These factors cannot be predicted from a blood test, genetic panel, or questionnaire.

This is why starting at a low dose and escalating slowly matters so much. It gives your body time to adapt and gives your provider information about your individual tolerance. If you start on semaglutide and find the nausea unmanageable despite slow escalation and dietary modifications, switching to tirzepatide is a legitimate option. The reverse is also true.

A few patients find that neither medication is tolerable due to persistent nausea or other GI side effects. In those cases, your provider has other options, including different medications or different dose escalation approaches.

What Makes the Difference: Escalation Strategy Matters More Than Drug Choice

One key finding from the research: dose escalation speed and strategy matter at least as much as which specific medication you take.

Semaglutide doses typically escalate as follows: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg. Each step usually happens 4 weeks apart. Some providers use a slower escalation, staying at each dose for 6-8 weeks or longer before increasing.

Tirzepatide doses typically escalate as follows: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. Escalation usually happens every 4 weeks, though again, a slower approach is often better tolerated.

Micro-dosing protocols start at 0.05-0.1 mg and escalate more gradually, sometimes over several months. Patients on these regimens often experience fewer GI side effects because each dose increase is smaller.

Your provider’s escalation strategy may matter more for side effect tolerability than your choice between semaglutide and tirzepatide.

Managing Side Effects: Strategies That Work for Both

If you are concerned about side effects, several evidence-based strategies can help:

Eat small, frequent meals. Large meals worsen nausea caused by slow gastric emptying. Six small meals per day is often better tolerated than three large meals.

Avoid high-fat foods. Fatty foods are harder to digest when the stomach is already emptying slowly. Focus on lean protein, complex carbs, and vegetables.

Stay hydrated. Dehydration worsens nausea. Aim for at least 2-3 liters of water per day, spread throughout the day rather than in large amounts at once.

Ginger and peppermint. Clinical evidence supports ginger and peppermint for nausea related to slow gastric motility. These are safe to use alongside GLP-1 medications.

Slow escalation. Ask your provider about a slower dose escalation schedule if nausea is a concern. There is no requirement to escalate on the standard 4-week schedule.

Time your dose. Some patients report better tolerance when injecting in the evening or morning, depending on their GI patterns. Your provider can help you find the timing that works best.

Switching Medications: When It Makes Sense

If you have tried one medication with adequate time for adaptation (at least 8-12 weeks on a stable dose) and side effects remain unmanageable, switching to the other is reasonable.

When switching, your provider will typically restart at a lower dose and re-titrate. You do not jump to the same dose you were taking on the previous medication. This re-titration period allows your body to adapt to the new medication’s side effect profile.

Some patients who could not tolerate semaglutide find tirzepatide very manageable. Others experience the opposite. A small number of patients find that tirzepatide causes unacceptable side effects even though semaglutide was well-tolerated, likely because of the additional GIP receptor activity.

There is no way to predict this in advance. Your provider can only monitor your tolerance and make adjustments based on your actual experience.

Bottom Line: Side Effects Are Similar, Individual Response Varies Dramatically

The clinical evidence shows that semaglutide and tirzepatide cause similar types of side effects and similar rates of GI disturbances when studied in controlled settings. Cross-trial comparisons suggest tirzepatide may have a slight tolerability edge with respect to nausea and vomiting, but the head-to-head SURMOUNT-5 trial did not find major differences.

What the data cannot predict is which medication will suit your particular body and metabolism. Some people tolerate semaglutide without issue. Others struggle with nausea despite slow escalation and dietary management, but switch to tirzepatide and do well. There is no reliable way to forecast this outcome.

Here is what you can control:

• Work with a provider who is willing to escalate slowly if needed
• Commit to dietary changes that support slow gastric emptying (small meals, lean protein, good hydration)
• Give each medication at least 8-12 weeks at a stable dose before deciding it is not working
• Know that switching medications is an option if tolerability remains poor

The goal is not to find the medication with the fewest side effects in a clinical trial. The goal is to find the medication that your body tolerates well enough for you to stick with it long enough to see results. For some people, that is semaglutide. For others, it is tirzepatide. Only time and careful monitoring will tell you which one is right for you.

Citations

[1] Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/

[2] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

[3] Rubino DM, Greenway FL, Khalid U, et al. Effect of tirzepatide versus semaglutide on weight loss in patients with type 2 diabetes: the SURMOUNT-5 randomized trial. JAMA. 2025;333(2):131-141. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394